l 778,123 has been researched along with bms 214662 in 10 studies
| Studies (l 778,123) | Trials (l 778,123) | Recent Studies (post-2010) (l 778,123) | Studies (bms 214662) | Trials (bms 214662) | Recent Studies (post-2010) (bms 214662) |
|---|---|---|---|---|---|
| 23 | 3 | 2 | 49 | 8 | 9 |
| 15 | 0 | 5 | 49 | 8 | 9 |
| Protein | Taxonomy | l 778,123 (IC50) | bms 214662 (IC50) |
|---|---|---|---|
| GTPase HRas | Homo sapiens (human) | 0.0013 | |
| GTPase KRas | Homo sapiens (human) | 0.7723 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 0.3617 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.0021 | |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernhard, E; Hahn, SM; McKenna, WG | 1 |
| Adjei, AA; Dy, GK; Haluska, P | 1 |
| Kelland, LR | 1 |
| Elhamri, M; Thomas, X | 1 |
| Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P | 1 |
| Appels, NM; Beijnen, JH; Schellens, JH | 1 |
| Dallmann, I; Ganser, A; Morgan, MA; Onono, FO; Reuter, CW; Scherr, M; Spielmann, HP; Subramanian, T; Venturini, L | 1 |
| Bauch, JL; Cohen, J; Gu, WZ; Hutchins, CW; Jakob, CG; Leonard, NM; Li, Q; Lin, NH; Marsh, K; Park, D; Rosenberg, SH; Sham, HL; Stoll, VS; Sullivan, G; Tong, Y; Wang, GT; Wang, L; Wang, X; Zhang, H | 1 |
| Bell, IM | 1 |
| Korzeniecki, C; Priefer, R | 1 |
8 review(s) available for l 778,123 and bms 214662
| Article | Year |
|---|---|
Farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2001 |
Farnesyl transferase inhibitors as anticancer agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured | 2002 |
Farnesyl transferase inhibitors in the treatment of breast cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2003 |
[Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Topics: Alkyl and Aryl Transferases; Benzodiazepines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Myeloproliferative Disorders; Piperidines; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Quinolones; ras Proteins; rho GTP-Binding Proteins | 2005 |
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins | 2005 |
Development of farnesyl transferase inhibitors: a review.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins | 2005 |
Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Design; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms | 2004 |
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |
2 other study(ies) available for l 778,123 and bms 214662
| Article | Year |
|---|---|
Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.
Topics: Anthracyclines; Antigens, Neoplasm; Apoptosis; Benzodiazepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dimethylallyltranstransferase; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Synergism; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Imidazoles; Leukemia, Myeloid; MAP Kinase Signaling System; Poly-ADP-Ribose Binding Proteins; Protein Prenylation | 2012 |
Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Benzamides; Biological Availability; Cell Membrane Permeability; Crystallography, X-Ray; Dogs; Drug Design; Farnesyltranstransferase; Imidazoles; Models, Molecular; Molecular Structure; Nitriles; Structure-Activity Relationship | 2004 |